OLX Group (“OLX”), a global online classifieds leader and subsidiary of Prosus N.V., has reported strong financial results in the fiscal year 20251. The company generated revenues of US$7772 million, an 18% year-on-year increase. Adjusted EBIT3 (aEBIT) amounted to US$2702 million, representing an increase of 61% (in local currency) over the prior year, while aEBIT margin was 35%, a significant expansion from 25% in FY24. The strong performance was primarily driven by its core categories Motor...

Sangfor Technologies, a leading global provider of cybersecurity and cloud computing solutions, proudly announces the launch of Sangfor Athena, the new brand identity for its cybersecurity business. This new brand brings together Sangfor’s advanced security technologies under one unified name, marking a strategic evolution in its commitment to delivering intelligent, integrated, and proactive cyber defense. The Sangfor Athena brand was first introduced through a soft launch during the recent ...

Global cloud communications platform Infobip has today released findings from a new study conducted by Harvard Business Review Analytic Services (HBR-AS) revealing a sharp disconnect in customer experience (CX): while 93% of those surveyed from the HBR audience recognize the high importance of creating positive conversational experiences, only 36% believe their organization is highly effective at it. Even more striking, just 11% report they’re highly effective using AI to deliver human-like con...

Brighter Signals B.V. (https://www.brightersignals.com), a sensing technology startup founded by serial entrepreneurs Andrew Klein, Christine Fraser and Edward Shim, today announced its launch and the acquisition of a breakthrough portfolio of patents for high-depth multi-modal tactile sensors made wholly of fabrics. Backed by early-stage VC firm Antler, Brighter Signals has developed a sensor platform over ten years that offers unprecedented high-depth tactile sensitivity, flexibility, and e...

Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to prov...

iFIT, a global leader in connected fitness and interactive content, today announced a groundbreaking partnership with Samsung Health, one of the world’s most recognized names in technology. This strategic collaboration aims to redefine how millions of users around the world experience personalized health and wellness. "Our collaboration with iFIT highlights Samsung’s unwavering commitment to preventive health and fitness for all. Through Samsung Health, we aim to provide highly personalized f...

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of IBKR InvestMentor, a new mobile microlearning app developed by its wholly owned subsidiary, Interactive Academy LLC. Currently available for iOS, IBKR InvestMentor offers free, accessible educational content to beginner and aspiring investors through short, interactive lessons that build foundational knowledge in economics and investing. This press release features multimedia. View the full...

TH Global Capital, an award-winning global boutique investment bank with a presence in 13 countries, has closed four high profile deals in the first four months of 2025, including the sale of The Missing Link to Infosys for 120 million AUD. This marks its tenth cross border transaction in Australia over the past 18 months, cementing its position as the mid-market M&A boutique investment bank of choice in Australia and New Zealand. Sale of The Missing Link to Infosys – The Missing Link, a...

Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years.1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET. ...